Transcriptional regulation of foxp3 gene: Multiple signal pathways on the road

Medicinal Research Reviews

Volumn 29, Issue 5, 2009, Pages 742-766

  Shen, Zhu ^a   Chen, Ling ^b   Hao, Fei ^a   Wu, Jinjin ^b  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Foxp3 gene; Immune; Signal pathway; Transcription regulation

Indexed keywords

CD4 ANTIGEN; ESTRADIOL; GLUCOCORTICOID; INTERFERON; INTERFERON REGULATORY FACTOR; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; JANUS KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NOTCH RECEPTOR; NOTCH1 RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTAGLANDIN E2; PROTEIN KINASE B; RETINOIC ACID; SMAD PROTEIN; STAT PROTEIN; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR GATA 3; TRANSFORMING GROWTH FACTOR BETA;

EPIGENETICS; HUMAN; METHYLATION; NONHUMAN; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; TH17 CELL; TH2 CELL; TRANSCRIPTION REGULATION;

ANIMALS; CYTOKINES; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION; HUMANS; INTERFERON-GAMMA; PROTEIN KINASES; RECEPTORS, INTERLEUKIN-2; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; SMAD PROTEINS; STAT TRANSCRIPTION FACTORS; T-LYMPHOCYTES, REGULATORY; TRANSCRIPTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA;

EID: 69449096138     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.20152     Document Type: Review

References (157)

1. Clark RA, Huang SJ, Murphy GF, Mollet IG, Hijnen D, Muthukuru M, Schanbacher CF, Edwards V, Miller DM, Kim JE, Lambert J, Kupper TS. Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells. J Exp Med 2008;205:2221-2234.
2. Hinz S, Pagerols-Raluy L, Oberg HH, Ammerpohl O, Grüssel S, Sipos B, Grützmann R, Pilarsky C, Ungefroren H, Saeger HD, Klöppel G, Kabelitz D, Kalthoff H. Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res 2007;67:8344-8350. (Pubitemid 47395173)
3. Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, Fehervari Z, Shimizu J, Takahashi T, Nomura T. Foxp3+CD25+CD4+natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 2006;212:8-27.
4. Williams LM, Rudensky AY. Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat Immunol 2007;8:277-284.
5. Wu Y, Borde M, Heissmeyer V, Feuerer M, Lapan AD, Stroud JC, Bates DL, Guo L, Han A, Ziegler SF, Mathis D, Benoist C, Chen L, Rao A. FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 2006;126:375-387. (Pubitemid 44092960)
6. Bettelli E, Dastrange M, Oukka M. Foxp3 interacts with nuclear factor of activated T cells and NF-kappa B to repress cytokine gene expression and effector functions of T helper cells. Proc Natl Acad Sci USA 2005;102:5138-5143. (Pubitemid 40503752)
7. Ono M, Yaguchi H, Ohkura N, Kitabayashi I, Nagamura Y, Nomura T, Miyachi Y, Tsukada T, Sakaguchi S. Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1. Nature 2007;446:685-689. (Pubitemid 46606883)
8. Li B, Samanta A, Song X, Iacono KT, Bembas K, Tao R, Basu S, Riley JL, Hancock WW, Shen Y, Saouaf SJ, Greene MI. FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression. Proc Natl Acad Sci USA 2007;104:4571-4576. (Pubitemid 47186266)
9. Mantel PY, Ouaked N, Rückert B, Karagiannidis C, Welz R, Blaser K, Schmidt-Weber CB. Molecular mechanisms underlying FOXP3 induction in human T cells. J Immunol 2006;176:3593-3602. (Pubitemid 43364007)
10. Jain J, Miner Z, Rao A. Analysis of the preexisting and nuclear forms of nuclear factor of activated T cells. J Immunol 1993;151:837-848. (Pubitemid 23215749)
11. Rooney JW, Hoey T, Glimcher LH. Coordinate and cooperative roles for NF-AT and AP-1 in the regulation of the murine IL-4 gene. Immunity 1995;2:473-483.
12. Dolganov G, Bort S, Lovett M, Burr J, Schubert L, Short D, McGurn M, Gibson C, Lewis DB. Coexpression of the interleukin-13 and interleukin-4 genes correlates with their physical linkage in the cytokine gene cluster on human chromosome 5q23-31. Blood 1996;87:3316-3326. (Pubitemid 26115362)
13. Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 2004;4:665-674.
14. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005;6:1142-1151. (Pubitemid 41541792)
15. Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+CD25(hi) Foxp3+regulatory T cells in cancer patients. Blood 2006;107:2409-2414.
16. Sereti I, Imamichi H, Natarajan V, Imamichi T, Ramchandani MS, Badralmaa Y, Berg SC, Metcalf JA, Hahn BK, Shen JM, Powers A, Davey RT, Kovacs JA, Shevach EM, Lane HC. In vivo expansion of CD4CD45RO-CD25 T cells expressing foxP3 in IL-2-treated HIV-infected patients. J Clin Invest 2005;115:1839-1847.
17. Zorn E, Nelson EA, Mohseni M, Porcheray F, Kim H, Litsa D, Bellucci R, Raderschall E, Canning C, Soiffer RJ, Frank DA, Ritz J. IL-2 regulates FOXP3 expression in human CD4+CD25+regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 2006;108:1571-1579. (Pubitemid 44316124)
18. Malek TR, Yu A, Zhu L, Matsutani T, Adeegbe D, Bayer AL. IL-2 Family of cytokines in T regulatory cell development and homeostasis. J Clin Immunol 2008. DOI: 10.1007/s10875-008-9235-y. Epub ahead of print.
19. Burchill MA, Yang J, Vogtenhuber C, Blazar BR, Farrar MA. IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+regulatory T cells. J Immunol 2007;178:280-290. (Pubitemid 46033611)
20. D'Cruz LM, Klein L. Development and function of agonist-induced CD25+Foxp3+regulatory T cells in the absence of interleukin 2 signaling. Nat Immunol 2005;6:1152-1159. (Pubitemid 41541793)
21. Zambricki E, Shigeoka A, Kishimoto H, Sprent J, Burakoff S, Carpenter C, Milford E, McKay D. Signaling T-cell survival and death by IL-2 and IL-15. Am J Transplant 2005;5:2623-2631. (Pubitemid 43920055)
22. Wuest TY, Willette-Brown J, Durum SK, Hurwitz AA. The influence of IL-2 family cytokines on activation and function of naturally occurring regulatory T cells. J Leukoc Biol 2008;84:973-980.
23. Frank DA, Robertson MJ, Bonni A, Ritz J, Greenberg ME. Interleukin 2 signaling involves the phosphorylation of Stat proteins. Proc Natl Acad Sci USA 1995;92:7779-7783.
24. Tsuji-Takayama K, Suzuki M, Yamamoto M, Harashima A, Okochi A, Otani T, Inoue T, Sugimoto A, Toraya T, Takeuchi M, Yamasaki F, Nakamura S, Kibata M. The production of IL-10 by human regulatory T cells is enhanced by IL-2 through a STAT5-responsive intronic enhancer in the IL-10 locus. J Immunol 2008;181:3897-3905.
25. Nelson EA, Walker SR, Alvarez JV, Frank DA. Isolation of unique STAT5 targets by chromatin immunoprecipitation-based gene identification. J Biol Chem 2004;279:54724-54730.
26. Nishihara M, Ogura H, Ueda N, Tsuruoka M, Kitabayashi C, Tsuji F, Aono H, Ishihara K, Huseby E, Betz UA, Murakami M, Hirano T. IL-6-gp130-STAT3 in T cells directs the development of IL-17+Th with a minimum effect on that of Treg in the steady state. Int Immunol 2007;19:695-702. (Pubitemid 47078714)
27. Passerini L, Allan SE, Battaglia M, Di Nunzio S, Alstad AN, Levings MK, Roncarolo MG, Bacchetta R. STAT5-signaling cytokines regulate the expression of FOXP3 in CD4+CD25+regulatory T cells and CD4+CD25-effector T cells. Int Immunol 2008;20:421-431.
28. Snow JW, Abraham N, Ma MC, Herndier BG, Pastuszak AW, Goldsmith MA. Loss of tolerance and autoimmunity affecting multiple organs in STAT5A/5B-deficient mice. J Immunol 2003;171:5042-5050. (Pubitemid 37432785)
29. Yao Z, Kanno Y, Kerenyi M, Stephens G, Durant L, Watford WT, Laurence A, Robinson GW, Shevach EM, Moriggl R, Hennighausen L, Wu C, O'Shea JJ. Nonredundant roles for Stat5a/b in directly regulating Foxp3. Blood 2007;109:4368-4375. (Pubitemid 46743405)
30. Kasprzycka M, Marzec M, Liu X, Zhang Q, Wasik MA. Nucleophosmin/ anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3. Proc Natl Acad Sci USA 2006;103:9964-9969. (Pubitemid 43993606)
31. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, Niu G, Kay H, Mulé J, Kerr WG, Jove R, Pardoll D, Yu H. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005;11:1314-1321. (Pubitemid 41752912)
32. Pallandre JR, Brillard E, Créhange G, Radlovic A, Remy-Martin JP, Saas P, Rohrlich PS, Pivot X, Ling X, Tiberghien P, Borg C. Role of STAT3 in CD4+CD25+FOXP3+regulatory lymphocyte generation: Implications in graft-versus-host disease and antitumor immunity. J Immunol 2007;179:7593-7604.
33. Yang XO, Panopoulos AD, Nurieva R, Chang SH, Wang D, Watowich SS, Dong C. STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J Biol Chem 2007;282:9358-9363.
34. Bayer AL, Lee JY, de la Barrera A, Surh CD, Malek TR. A function for IL-7R for CD4+CD25+Foxp3+T regulatory cells. J Immunol 2008;181:225-234.
35. Imamichi H, Sereti I, Lane HC. IL-15 acts as a potent inducer of CD4(+)CD25(hi) cells expressing FOXP3. Eur J Immunol 2008;38:1621-1630.
36. Mazzucchelli R, Hixon JA, Spolski R, Chen X, Li WQ, Hall VL, Willette-Brown J, Hurwitz AA, Leonard WJ, Durum SK. Development of regulatory T cells requires IL-7Ralpha stimulation by IL-7 or TSLP. Blood 2008;112:3283-3292.
37. Dooms H, Wolslegel K, Lin P, Abbas AK. Interleukin-2 enhances CD4+T cell memory by promoting the generation of IL-7R alpha-expressing cells. J Exp Med 2007;204:547-557. (Pubitemid 46457078)
38. Chen Z, Laurence A, O'Shea JJ. Signal transduction pathways and transcriptional regulation in the control of Th17 differentiation. Semin Immunol 2007;19:400-408.
39. Yang L, Anderson DE, Baecher-Allan C, Hastings WD, Bettelli E, Oukka M, Kuchroo VK, Hafler DA. IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature 2008;454:350-352.
40. Scheeren FA, Diehl SA, Smit LA, Beaumont T, Naspetti M, Bende RJ, Blom B, Karube K, Ohshima K, van Noesel CJ, Spits H. IL-21 is expressed in Hodgkin lymphoma and activates STAT5: Evidence that activated STAT5 is required for Hodgkin lymphomagenesis. Blood 2008;111:4706-4715.
41. Kang SG, Lim HW, Andrisani OM, Broxmeyer HE, Kim CH. Vitamin A metabolites induce guthoming FoxP3+regulatory T cells. J Immunol 2007;179:3724-3733.
42. Takaki H, Ichiyama K, Koga K, Chinen T, Takaesu G, Sugiyama Y, Kato S, Yoshimura A, Kobayashi T. STAT6 inhibits TGF-beta1-mediated Foxp3 induction through direct binding to the Foxp3 promoter, which is reverted by retinoic acid receptor. J Biol Chem 2008;283:14955-14962.
43. Mantel PY, Kuipers H, Boyman O, Rhyner C, Ouaked N, Rückert B, Karagiannidis C, Lambrecht BN, Hendriks RW, Crameri R, Akdis CA, Blaser K, Schmidt-Weber CB. GATA3-driven Th2 responses inhibit TGF-beta1-induced FOXP3 expression and the formation of regulatory T cells. PLoS Biol 2007;5:e329. (Pubitemid 351159712)
44. Skapenko A, Kalden JR, Lipsky PE, Schulze-Koops H. The IL-4 receptor alpha-chain-binding cytokines, IL-4 and IL-13, induce forkhead box P3-expressing CD25+CD4+regulatory T cells from CD25-CD4+precursors. J Immunol 2005;175:6107-6116.
45. Maerten P, Shen C, Bullens DM, Van Assche G, Van Gool S, Geboes K, Rutgeerts P, Ceuppens JL. Effects of interleukin 4 on CD25+CD4+regulatory T cell function. J Autoimmun 2005;25:112-120.
46. Pace L, Pioli C, Doria G. IL-4 modulation of CD4+CD25+T regulatory cell-mediated suppression. J Immunol 2005;174:7645-7653.
47. Kasprzycka M, Zhang Q, Witkiewicz A, Marzec M, Potoczek M, Liu X, Wang HY, Milone M, Basu S, Mauger J, Choi JK, Abrams JT, Hou JS, Rook AH, Vonderheid E, Woetmann A, Odum N, Wasik MA. Gamma c-signaling cytokines induce a regulatory T cell phenotype in malignant CD4+T lymphocytes. J Immunol 2008;181:2506-2512.
48. Valentino L, Pierre J. JAK/STAT signal transduction: Regulators and implication in hematological malignancies. Biochem Pharmacol 2006;71:713-721. (Pubitemid 43208827)
49. Chung CD, Liao J, Liu B, Rao X, Jay P, Berta P, Shuai K. Specific inhibition of Stat3 signal transduction by PIAS3. Science 1997;278:1803-1805. (Pubitemid 27527648)
50. Antov A, Yang L, Vig M, Baltimore D, Van Parijs L. Essential role for STAT5 signaling in CD25+CD4+regulatory T cell homeostasis and the maintenance of self-tolerance. J Immunol 2003;171:3435-3441. (Pubitemid 37254544)
51. Bensinger SJ, Walsh PT, Zhang J, Carroll M, Parsons R, Rathmell JC, Thompson CB, Burchill MA, Farrar MA, Turka LA. Distinct IL-2 receptor signaling pattern in CD4+CD25+regulatory T cells. J Immunol 2004;172:5287-5296.
52. Yates J, Rovis F, Mitchell P, Afzali B, Tsang JY, Garin M, Lechler RI, Lombardi G, Garden OA. The maintenance of human CD4+CD25+regulatory T cell function: IL-2, IL-4, IL-7 and IL-15 preserve optimal suppressive potency in vitro. Int Immunol 2007;19:785-799. (Pubitemid 47073268)
53. Massagué J, Blain SW, Lo RS. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 2000;103:295-309.
54. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003;425:577-584. (Pubitemid 37280136)
55. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM. Conversion of peripheral CD4+CD25-naive T cells to CD4+CD25+regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003;198:1875-1886.
56. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006;24:179-189. (Pubitemid 43214587)
57. Zhou L, Lopes JE, Chong MM, Ivanov II, Min R, Victora GD, Shen Y, Du J, Rubtsov YP, Rudensky AY, Ziegler SF, Littman DR. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 2008;453:236-240. (Pubitemid 351667978)
58. Mucida D, Park Y, Kim G, Turovskaya O, Scott I, Kronenberg M, Cheroutre H. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 2007;317:256-260. (Pubitemid 47076203)
59. Xiao S, Jin H, Korn T, Liu SM, Oukka M, Lim B, Kuchroo VK. Retinoic acid increases Foxp3+regulatory T cells and inhibits development of Th17 cells by enhancing TGF-beta-driven Smad3 signaling and inhibiting IL-6 and IL-23 receptor expression. J Immunol 2008;181:2277-2284.
60. Schramm C, Huber S, Protschka M, Czochra P, Burg J, Schmitt E, Lohse AW, Galle PR, Blessing M. TGFbeta regulates the CD4+CD25+T-cell pool and the expression of Foxp3 in vivo. Int Immunol 2004;16:1241-1249. (Pubitemid 39220423)
61. Yamagiwa S, Gray JD, Hashimoto S, Horwitz DA. A role for TGF-beta in the generation and expansion of CD4+CD25+regulatory T cells from human peripheral blood. J Immunol 2001;166:7282-7289. (Pubitemid 32525603)
62. Marie JC, Letterio JJ, Gavin M, Rudensky AY. TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+regulatory T cells. J Exp Med 2005;201:1061-1067.
63. Huber S, Schramm C, Lehr HA, Mann A, Schmitt S, Becker C, Protschka M, Galle PR, Neurath MF, Blessing M. Cutting edge: TGF-beta signaling is required for the in vivo expansion and immunosuppressive capacity of regulatory CD4+CD25+T cells. J Immunol 2004;173:6526-6531. (Pubitemid 39541034)
64. Kretschmer K, Apostolou I, Hawiger D, Khazaie K, Nussenzweig MC, von Boehmer H. Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol 2005;6: 1219-1227. (Pubitemid 43045633)
65. Amarnath S, Dong L, Li J, Wu Y, Chen W. Endogenous TGF-beta activation by reactive oxygen species is key to Foxp3 induction in TCR-stimulated and HIV-1-infected human CD4+CD25-T cells. Retrovirology 2007;4:57. (Pubitemid 350193339)
66. Derynck R, Zhang Y, Feng XH. Smads: Transcriptional activators of TGF-beta responses. Cell 1998;95:737-740. (Pubitemid 29014453)
67. Anthoni M, Fyhrquist-Vanni N, Wolff H, Alenius H, Lauerma A. Transforming growth factor-beta/Smad3 signalling regulates inflammatory responses in a murine model of contact hypersensitivity. Br J Dermatol 2008;159:546-554.
68. Tone Y, Furuuchi K, Kojima Y, Tykocinski ML, Greene MI, Tone M. Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. Nat Immunol 2008;9:194-202.
69. von Boehmer H, Nolting J. What turns on Foxp3? Nat Immunol 2008;9:121-122.
70. Licona-Limón P, Soldevila G. The role of TGF-beta superfamily during T cell development: New insights. Immunol Lett 2007;109:1-12. (Pubitemid 46365965)
71. Dominitzki S, Fantini MC, Neufert C, Nikolaev A, Galle PR, Scheller J, Monteleone G, Rose-John S, Neurath MF, Becker C. Cutting edge: Trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4+CD25 T cells. J Immunol 2007;179:2041-2045.
72. Benson MJ, Pino-Lagos K, Rosemblatt M, Noelle RJ. All-trans retinoic acid mediates enhanced T reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation. J Exp Med 2007;204:1765-1774. (Pubitemid 47236315)
73. Mucida D, Park Y, Cheroutre H. From the diet to the nucleus: Vitamin A and TGF-beta join efforts at the mucosal interface of the intestine. Semin Immunol 2008. DOI: 10.1016/j.smim.2008.08.001. Epub ahead of print.
74. Schambach F, Schupp M, Lazar MA, Reiner SL. Activation of retinoic acid receptor-alpha favours regulatory T cell induction at the expense of IL-17-secreting T helper cell differentiation. Eur J Immunol 2007;37:2396-2399. (Pubitemid 47423609)
75. Hill JA, Hall JA, Sun CM, Cai Q, Ghyselinck N, Chambon P, Belkaid Y, Mathis D, Benoist C. Retinoic acid enhances Foxp3 induction indirectly by relieving inhibition from CD4+CD44hi Cells. Immunity 2008;29:758-770.
76. von Boehmer H. Notch in lymphopoiesis and T cell polarization. Nat Immunol 2005;6:641-642.
77. Anastasi E, Campese AF, Bellavia D, Bulotta A, Balestri A, Pascucci M, Checquolo S, Gradini R, Lendahl U, Frati L, Gulino A, Di Mario U, Screpanti I. Expression of activated Notch3 in transgenic mice enhances generation of T regulatory cells and protects against experimental autoimmune diabetes. J Immunol 2003;171:4504-4511. (Pubitemid 37310565)
78. Vigouroux S, Yvon E, Wagner HJ, Biagi E, Dotti G, Sili U, Lira C, Rooney CM, Brenner MK. Induction of antigen-specific regulatory T cells following overexpression of a Notch ligand by human B lymphocytes. J Virol 2003;77:10872-10880. (Pubitemid 37204280)
79. Asano N, Watanabe T, Kitani A, Fuss IJ, Strober W. Notch1 signaling and regulatory T cell function. J Immunol 2008;180:2796-2804.
80. Ou-Yang HF, Zhang HW, Wu CG, Zhang P, Zhang J, Li JC, Hou LH, He F, Ti XY, Song LQ, Zhang SZ, Feng L, Qi HW, Han H. Notch signaling regulates the FOXP3 promoter through RBP-J- and Hes1-dependent mechanisms. Mol Cell Biochem 2008. DOI: 10.1007/s11010-008-9912-4. Epub ahead of print.
81. Ostroukhova M, Qi Z, Oriss TB, Dixon-McCarthy B, Ray P, Ray A. Treg-mediated immunosuppression involves activation of the Notch-HES1 axis by membrane-bound TGF-beta. J Clin Invest 2006;116:996-1004.
82. Blokzijl A, Dahlqvist C, Reissmann E, Falk A, Moliner A, Lendahl U, Ibáñez CF. Cross-talk between the Notch and TGF-beta signaling pathways mediated by interaction of the Notch intracellular domain with Smad3. J Cell Biol 2003;163:723-728. (Pubitemid 37517880)
83. Samon JB, Champhekar A, Minter LM, Telfer JC, Miele L, Fauq A, Das P, Golde TE, Osborne BA. Notch1 and TGFbeta1 cooperatively regulate Foxp3 expression and the maintenance of peripheral regulatory T cells. Blood 2008;112:1813-1821.
84. Maruyama S, Sumita K, Shen H, Kanoh M, Xu X, Sato M, Matsumoto M, Shinomiya H, Asano Y. Identification of IFN regulatory factor-1 binding site in IL-12 p40 gene promoter. J Immunol 2003;170:997-1001. (Pubitemid 36070554)
85. Brüstle A, Heink S, Huber M, Rosenplänter C, Stadelmann C, Yu P, Arpaia E, Mak TW, Kamradt T, Lohoff M. The development of inflammatory T(H)-17 cells requires interferon-regulatory factor 4. Nat Immunol 2007;8:958-966. (Pubitemid 47300010)
86. Rengarajan J, Mowen KA, McBride KD, Smith ED, Singh H, Glimcher LH. Interferon regulatory factor 4 (IRF4) interacts with NFATc2 to modulate interleukin 4 gene expression. J Exp Med 2002;195:1003-1012. (Pubitemid 34412002)
87. Fragale A, Gabriele L, Stellacci E, Borghi P, Perrotti E, Ilari R, Lanciotti A, Remoli AL, Venditti M, Belardelli F, Battistini A. IFN regulatory factor-1 negatively regulates CD4+CD25+regulatory T cell differentiation by repressing Foxp3 expression. J Immunol 2008;181:1673-1682.
88. Feng G, Gao W, Strom TB, Oukka M, Francis RS, Wood KJ, Bushell A. Exogenous IFN-gamma ex vivo shapes the alloreactive T-cell repertoire by inhibition of Th17 responses and generation of functional Foxp3(+) regulatory T cells. Eur J Immunol 2008;38:2512-2527.
89. Liew FY. Regulation of lymphocyte functions by nitric oxide. Curr Opin Immunol 1995;7:396-399.
90. Nathan C, Xie QW. Nitric oxide synthases: Roles, tolls, and controls. Cell 1994;78:915-918. (Pubitemid 24292319)
91. Bronte V, Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 2005;5:641-654. (Pubitemid 41113195)
92. Robertson G, Hirst M, Bainbridge M, Bilenky M, Zhao Y, Zeng T, Euskirchen G, Bernier B, Varhol R, Delaney A, Thiessen N, Griffith OL, He A, Marra M, Snyder M, Jones S. Genomewide profiles of STAT1 DNA association using chromatin immunoprecipitation and massively parallel sequencing. Nat Methods 2007;4:651-657. (Pubitemid 47202477)
93. Niedbala W, Cai B, Liu H, Pitman N, Chang L, Liew FY. Nitric oxide induces CD4+CD25+Foxp3 regulatory T cells from CD4+CD25 T cells via p53, IL-2, and OX40. Proc Natl Acad Sci USA 2007;104:15478-15483.
94. Feng G, Wood KJ, Bushell A. Interferon-gamma conditioning ex vivo generates CD25+CD62L+Foxp3+regulatory T cells that prevent allograft rejection: Potential avenues for cellular therapy. Transplantation 2008;86:578-589.
95. Guillonneau C, Hill M, Hubert FX, Chiffoleau E, Hervé C, Li XL, Heslan M, Usal C, Tesson L, Ménoret S, Saoudi A, Le Mauff B, Josien R, Cuturi MC, Anegon I. CD40Ig treatment results in allograft acceptance mediated by CD8CD45RC T cells, IFN-gamma, and indoleamine 2,3-dioxygenase. J Clin Invest 2007;117:1096-1106. (Pubitemid 46556766)
96. Thebault P, Condamine T, Heslan M, Hill M, Bernard I, Saoudi A, Josien R, Anegon I, Cuturi MC, Chiffoleau E. Role of IFNgamma in allograft tolerance mediated by CD4+CD25+regulatory T cells by induction of IDO in endothelial cells. Am J Transplant 2007;7:2472-2482. (Pubitemid 47561604)
97. Zhang J. Yin and yang interplay of IFN-gamma in inflammation and autoimmune disease. J Clin Invest 2007;117:871-873. (Pubitemid 46556742)
98. Kelchtermans H, Billiau A, Matthys P. How interferon-gamma keeps autoimmune diseases in check. Trends Immunol 2008;29:479-486.
99. Patel RK, Mohan C. PI3K/AKT signaling and systemic autoimmunity. Immunol Res 2005;31:47-55.
100. Wu T, Qin X, Kurepa Z, Kumar KR, Liu K, Kanta H, Zhou XJ, Satterthwaite AB, Davis LS, Mohan C. Shared signaling networks active in B cells isolated from genetically distinct mouse models of lupus. J Clin Invest 2007;117:2186-2196. (Pubitemid 47219563)
101. Patton DT, Garden OA, Pearce WP, Clough LE, Monk CR, Leung E, Rowan WC, Sancho S, Walker LS, Vanhaesebroeck B, Okkenhaug K. Cutting edge: The phosphoinositide 3-kinase p110 delta is critical for the function of CD4+CD25+Foxp3+regulatory T cells. J Immunol 2006;177:6598-6602.
102. Gao W, Lu Y, El Essawy B, Oukka M, Kuchroo VK, Strom TB. Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am J Transplant 2007;7:1722-1732. (Pubitemid 46905432)
103. Haxhinasto S, Mathis D, Benoist C. The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+cells. J Exp Med 2008;205:565-574.
104. Sauer S, Bruno L, Hertweck A, Finlay D, Leleu M, Spivakov M, Knight ZA, Cobb BS, Cantrell D, O'Connor E, Shokat KM, Fisher AG, Merkenschlager M. T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci USA 2008;105: 7797-7802. (Pubitemid 351872718)
105. Floess S, Freyer J, Siewert C, Baron U, Olek S, Polansky J, Schlawe K, Chang HD, Bopp T, Schmitt E, Klein-Hessling S, Serfling E, Hamann A, Huehn J. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol 2007;5:e38. (Pubitemid 46256667)
106. Reiner SL. Epigenetic control in the immune response. Hum Mol Genet 2005;14:R41-R46.
107. Tykocinski LO, Hajkova P, Chang HD, Stamm T, Sözeri O, Löhning M, Hu-Li J, Niesner U, Kreher S, Friedrich B, Pannetier C, Grütz G, Walter J, Paul WE, Radbruch A. A critical control element for interleukin-4 memory expression in T helper lymphocytes. J Biol Chem 2005;280:28177-28185. (Pubitemid 41105713)
108. Koenen HJ, Smeets RL, Vink PM, van Rijssen E, Boots AM, Joosten I. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 2008;112:2340-2352.
109. Supporting information for epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol. Web site: http://biology.plosjournals.org/ archive/1545-7885/5/2/supinfo/10.1371-journal.pbio.0050038.sg001.pdf. Accessed December 26, 2008.
110. Bruniquel D, Schwartz RH. Selective, stable demethylation of the interleukin-2 gene enhances transcription by an active process. Nat Immunol 2003;4:235-240. (Pubitemid 36322132)
111. Kim HP, Leonard WJ. CREB/ATF-dependent T cell receptor-induced FoxP3 gene expression: A role for DNA methylation. J Exp Med 2007;204:1543-1551. (Pubitemid 47048022)
112. Harris SG, Padilla J, Koumas L, Ray D, Phipps RP. Prostaglandins as modulators of immunity. Trends Immunol 2002;23:144-150.
113. Mahic M, Yaqub S, Johansson CC, Taskén K, Aandahl EM. FOXP3+CD4+CD25+adaptive regulatory T cells express cyclooxygenase-2 and suppress effector T cells by a prostaglandin E2-dependent mechanism. J Immunol 2006;177:246-254.
114. Dubinett SM, Sharma S, Huang M, Dohadwala M, Pold M, Mao JT. Cyclooxygenase-2 in lung cancer. Prog Exp Tumor Res 2003;37:138-162.
115. Sharma S, Huang M, Dohadwala M, Pold M, Batra RK, Dubinett SM. Cyclooxygenase 2-dependent regulation of antitumor immunity in lung cancer. Methods Mol Med 2003;75: 723-736.
116. Yaqub S, Henjum K, Mahic M, Jahnsen FL, Aandahl EM, Bjørnbeth BA, Taskén K. Regulatory T cells in colorectal cancer patients suppress anti-tumor immune activity in a COX-2 dependent manner. Cancer Immunol Immunother 2008;57:813-821. (Pubitemid 351660125)
117. Yokokawa J, Cereda V, Remondo C, Gulley JL, Arlen PM, Schlom J, Tsang KY. Enhanced functionality of CD4+CD25(high)FoxP3+regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res 2008;14:1032-1040.
118. Baratelli F, Lin Y, Zhu L, Yang SC, Heuzé-Vourc'h N, Zeng G, Reckamp K, Dohadwala M, Sharma S, Dubinett SM. Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+T cells. J Immunol 2005;175:1483-1490.
119. Sharma S, Yang SC, Zhu L, Reckamp K, Gardner B, Baratelli F, Huang M, Batra RK, Dubinett SM. Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+CD25+T regulatory cell activities in lung cancer. Cancer Res 2005;65: 5211-5220. (Pubitemid 40827331)
120. Bryn T, Yaqub S, Mahic M, Henjum K, Aandahl EM, Taskén K. LPS-activated monocytes suppress T-cell immune responses and induce FOXP3+T cells through a COX-2-PGE2-dependent mechanism. Int Immunol 2008;20:235-245. (Pubitemid 351234391)
121. Polanczyk MJ, Carson BD, Subramanian S, Afentoulis M, Vandenbark AA, Ziegler SF, Offner H. Cutting edge: Estrogen drives expansion of the CD4+CD25+regulatory T cell compartment. J Immunol 2004;173:2227-2230.
122. Polanczyk MJ, Hopke C, Huan J, Vandenbark AA, Offner H. Enhanced FoxP3 expression and Treg cell function in pregnant and estrogen-treated mice. J Neuroimmunol 2005;170: 85-92. (Pubitemid 41740909)
123. Tai P, Wang J, Jin H, Song X, Yan J, Kang Y, Zhao L, An X, Du X, Chen X, Wang S, Xia G, Wang B. Induction of regulatory T cells by physiological level estrogen. J Cell Physiol 2008; 214:456-464.
124. Polanczyk MJ, Hopke C, Vandenbark AA, Offner H. Estrogen-mediated immunomodulation involves reduced activation of effector T cells, potentiation of Treg cells, and enhanced expression of the PD-1 costimulatory pathway. J Neurosci Res 2006;84:370-378. (Pubitemid 44126289)
125. Polanczyk MJ, Hopke C, Vandenbark AA, Offner H. Treg suppressive activity involves estrogen-dependent expression of programmed death-1 (PD-1). Int Immunol 2007;19: 337-343. (Pubitemid 46344699)
126. Aragiannidis C, Akdis M, Holopainen P, Woolley NJ, Hense G, Rückert B, Mantel PY, Menz G, Akdis CA, Blaser K, Schmidt-Weber CB. Glucocorticoids upregulate FoxP3 expression and regulatory T cells in asthma. J Allergy Clin Immunol 2004;114:1425-1433. (Pubitemid 39575901)
127. Braitch M, Harikrishnan S, Robins RA, Nichols C, Fahey AJ, Showe L, Constantinescu CS. Glucocorticoids increase CD4(+)CD25(high) cell percentage and Foxp3 expression in patients with multiple sclerosis. Acta Neurol Scand 2008. DOI: 10.1111/j.1600-0404.2008.01090.x. Epub ahead of print.
128. Chen X, Oppenheim JJ, Winkler-Pickett RT, Ortaldo JR, Howard OM. Glucocorticoid amplifies IL-2-dependent expansion of functional FoxP3(+)CD4(+)CD25(+) T regulatory cells in vivo and enhances their capacity to suppress EAE. Eur J Immunol 2006;36: 2139-2149. (Pubitemid 44251759)
129. Ko K, Yamazaki S, Nakamura K, Nishioka T, Hirota K, Yamaguchi T, Shimizu J, Nomura T, Chiba T, Sakaguchi S. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+regulatory T cells. J Exp Med 2005;202:885-891.
130. Ramirez-Montagut T, Chow A, Hirschhorn-Cymerman D, Terwey TH, Kochman AA, Lu S, Miles RC, Sakaguchi S, Houghton AN, van den Brink MR. Glucocorticoidinduced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity. J Immunol 2006;176:6434-6442. (Pubitemid 43787825)
131. Xia ZW, Xu LQ, Zhong WW, Wei JJ, Li NL, Shao J, Li YZ, Yu SC, Zhang ZL. Heme oxygenase-1 attenuates ovalbumin-induced airway inflammation by up-regulation of foxp3 T-regulatory cells, interleukin-10, and membrane-bound transforming growth factor-1. Am J Pathol 2007;171:1904-1914.
132. Delgado M, Chorny A, Gonzalez-Rey E, Ganea D. Vasoactive intestinal peptide generates CD4+CD25+regulatory T cells in vivo. J Leukoc Biol 2005;78:1327-1338.
133. Fernandez-Martin A, Gonzalez-Rey E, Chorny A, Ganea D, Delgado M. Vasoactive intestinal peptide induces regulatory T cells during experimental autoimmune encephalomyelitis. Eur J Immunol 2006;36:318-326. (Pubitemid 43257454)
134. Gonzalez-Rey E, Fernandez-Martin A, Chorny A, Delgado M. Vasoactive intestinal peptide induces CD4+,CD25+T regulatory cells with therapeutic effect in collagen-induced arthritis. Arthritis Rheum 2006;54:864-876.
135. Ciancio G, Burke GW, Gaynor JJ, Carreno MR, Cirocco RE, Mathew JM, Mattiazzi A, Cordovilla T, Roth D, Kupin W, Rosen A, Esquenazi V, Tzakis AG, Miller J. A randomized trial of three renal transplant induction antibodies: Early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation 2005;80:457-465. (Pubitemid 41209412)
136. Anderson MK. At the crossroads: Diverse roles of early thymocyte transcriptional regulators. Immunol Rev 2006;209:191-211.
137. Selvaraj RK, Geiger TL. A kinetic and dynamic analysis of Foxp3 induced in T cells by TGF-beta. J Immunol 2007;179:11 following 1390.
138. Vindevoghel L, Kon A, Lechleider RJ, Uitto J, Roberts AB, Mauviel A. Smad-dependent transcriptional activation of human type VII collagen gene (COL7A1) promoter by transforming growth factor-beta. J Biol Chem 1998;273:13053-13057. (Pubitemid 28246870)
139. Wohlfert EA, Gorelik L, Mittler R, Flavell RA, Clark RB. Cutting edge: Deficiency in the E3 ubiquitin ligase Cbl-b results in a multifunctional defect in T cell TGF-beta sensitivity in vitro and in vivo. J Immunol 2006;176:1316-1320. (Pubitemid 43134271)
140. Zheng SG, Wang JH, Stohl W, Kim KS, Gray JD, Horwitz DA. TGF-beta requires CTLA-4 early after T cell activation to induce FoxP3 and generate adaptive CD4+CD25+regulatory cells. J Immunol 2006;176:3321-3329. (Pubitemid 43363978)
141. Du WM. The continuity of being: Chinese visions of nature. In: Callicott JB, Ames RT, editors. Nature in Asian traditions of thought. Albany, NY: State University Press of New York; 1989. pp 73-78.
142. Mao X. Lüshi chun qiu (Lü's Spring and Autumn), an important literature reflecting scientific culture of pre-Qin period. Zhonghua Yi Shi Za Zhi 2005;35:158-160.
143. Fiorentino DF. The Yin and Yang of TNF-(alpha) inhibition. Arch Dermatol 2007;143: 233-236.
144. Spolski R, Leonard WJ. The Yin and Yang of interleukin-21 in allergy, autoimmunity and cancer. Curr Opin Immunol 2008;20:295-301.
145. Guo F, Iclozan C, Suh WK, Anasetti C, Yu XZ. CD28 controls differentiation of regulatory T cells from naive CD4 T cells. J Immunol 2008;181:2285-2291.
146. Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A, Bluestone JA. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+immunoregulatory T cells that control autoimmune diabetes. Immunity 2000;12:431-440. (Pubitemid 30953967)
147. Scottà C, Soligo M, Camperio C, Piccolella E. FOXP3 induced by CD28/B7 interaction regulates CD25 and anergic phenotype in human CD4+CD25-T lymphocytes. J Immunol 2008;181:1025-1033.
148. Azuma H, Isaka Y, Li X, Hünig T, Sakamoto T, Nohmi H, Takabatake Y, Mizui M, Kitazawa Y, Ichimaru N, Ibuki N, Ubai T, Inamoto T, Katsuoka Y, Takahara S. Superagonistic CD28 antibody induces donor-specific tolerance in rat renal allografts. Am J Transplant 2008;8:2004-2014.
149. Kitazawa Y, Fujino M, Sakai T, Azuma H, Kimura H, Isaka Y, Takahara S, Hünig T, Abe R, Li XK. Foxp3-expressing regulatory T cells expanded with CD28 superagonist antibody can prevent rat cardiac allograft rejection. J Heart Lung Transplant 2008;27:362-371.
150. Waibler Z, Sender LY, Merten C, Hartig R, Kliche S, Gunzer M, Reichardt P, Kalinke U, Schraven B. Signaling signatures and functional properties of anti-human CD28 superagonistic antibodies. PLoS ONE 2008;3:e1708. (Pubitemid 351891300)
151. Rodríguez-Palmero M, Franch A, Castell M, Pelegrí C, Pérez-Cano FJ, Kleinschnitz C, Stoll G, Hünig T, Castellote C. Effective treatment of adjuvant arthritis with a stimulatory CD28-specific monoclonal antibody. J Rheumatol 2006;33:110-118. (Pubitemid 43054290)
152. Schraven B, Kalinke U. CD28 superagonists:What makes the difference in humans? Immunity 2008;28:591-595.
153. Müller N, van den Brandt J, Odoardi F, Tischner D, Herath J, Flügel A, Reichardt HM. A CD28 superagonistic antibody elicits 2 functionally distinct waves of T cell activation in rats. J Clin Invest 2008;118:1405-1416.
154. Istrail S, Davidson EH. Logic functions of the genomic cis-regulatory code. Proc Natl Acad Sci USA 2005;102:4954-4959. (Pubitemid 40503721)
155. Gavin MA, Clarke SR, Negrou E, Gallegos A, Rudensky A. Homeostasis and anergy of CD4(+) CD25(+) suppressor T cells in vivo. Nat Immunol 2002;3:33-41. (Pubitemid 34065615)
156. Capriotti E, Vonderheid EC, Thoburn CJ, Wasik MA, Bahler DW, Hess AD. Expression of T-plastin, FoxP3 and other tumor-associated markers by leukemic T-cells of cutaneous T-cell lymphoma. Leuk Lymphoma 2008;49:1190-1201.
157. Karanikas V, Speletas M, Zamanakou M, Kalala F, Loules G, Kerenidi T, Barda AK, Gourgoulianis KI, Germenis AE. Foxp3 expression in human cancer cells. J Transl Med 2008;6:19. (Pubitemid 351712556)